
Opinion|Videos|March 4, 2025
New Nonsteroidal Topical Treatment Options for Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD, Randy Alevi, DO
Panelists discuss recent topical atopic dermatitis therapies, which include roflumilast (PDE4 inhibitor, age ≥ 6 years), ruxolitinib (JAK inhibitor, age ≥ 12 years), and tapinarof (hydrocarbon receptor agonist, age ≥ 2 years). Treatment selection considers disease severity, age, affected areas, comorbidities, and previous therapy responses.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- There have been several new topical therapies approved in recent years. Discuss these treatments, how they work to treat atopic dermatitis, as well as an overview of efficacy and safety data.
- Topical roflumilast (0.15% cream): FDA approved for patients 6 years or older
- PDE4 inhibitor; INTEGUMENT-1 and INTEGUMENT-2
- Topical ruxolitinib (1.5% cream): FDA approved for patients 12 years or older
- JAK inhibitor; TRuE-AD1 and TRuE-AD2
- Topical tapinarof (1% cream): FDA approved for patients 2 years or older
- Hydrocarbon receptor agonist; ADORING 1 and ADORING 2
- Topical roflumilast (0.15% cream): FDA approved for patients 6 years or older
- What patient factors do you consider when selecting a treatment option?
- How do you decide among all the available topical treatment options for your patients?
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
ACOG Releases New Guidance on HIV Screening and Prevention
2
From Amyloid Clearance to Daytime Function: Why Sleep Quality Matters for Brain Health
3
2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults
4
FDA Accepts Cefiderocol sNDA for Pediatric Gram-Negative Infections
5


























































































































































